Back to Search
Start Over
Rectovaginal fistula in a cervical cancer patient treated with sequential radiotherapy and bevacizumab: A dose‐volume analysis
- Source :
- Clinical Case Reports, Clinical Case Reports, Vol 9, Iss 4, Pp 2099-2104 (2021)
- Publication Year :
- 2021
- Publisher :
- John Wiley and Sons Inc., 2021.
-
Abstract
- Bevacizumab is a monoclonal antibody against vascular endothelial growth factor that exerts antitumor effect by preventing tumor angiogenesis. Gastrointestinal fistula is a common side effect of bevacizumab in combination with radiotherapy. This case of rectovaginal fistula indicates that the side effect may be unpredictable by the conventional dose‐volume parameters for the rectum.
- Subjects :
- medicine.medical_specialty
Medicine (General)
Bevacizumab
Side effect
medicine.drug_class
cervical cancer
medicine.medical_treatment
Urology
Rectum
Case Report
Case Reports
030204 cardiovascular system & hematology
bevacizumab
Monoclonal antibody
dose‐volume analysis
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
R5-920
medicine
Cervical cancer
business.industry
rectovaginal fistula
General Medicine
medicine.disease
Vascular endothelial growth factor
Radiation therapy
radiation
medicine.anatomical_structure
chemistry
Rectovaginal fistula
030220 oncology & carcinogenesis
Medicine
business
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 20500904
- Volume :
- 9
- Issue :
- 4
- Database :
- OpenAIRE
- Journal :
- Clinical Case Reports
- Accession number :
- edsair.doi.dedup.....956b5c9267f22bcd6a1adb5b9d23d329